Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 48% Improvement Relative Risk Aspirin for COVID-19  Meizlish et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 638 patients in the USA Lower mortality with aspirin (p=0.004) c19early.org Meizlish et al., American J. Hematology, Jan 2021 Favors aspirin Favors control

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis

Meizlish et al., American Journal of Hematology, doi:10.1002/ajh.26102
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.00014 from 72 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 638 matched hospitalized patients in the USA, 319 treated with aspirin, showing lower mortality with treatment.
risk of death, 47.8% lower, HR 0.52, p = 0.004, treatment 319, control 319, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Meizlish et al., 21 Jan 2021, retrospective, propensity score matching, USA, peer-reviewed, 22 authors.
This PaperAspirinAll
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID ‐19: A propensity score‐matched analysis
Matthew L Meizlish, George Goshua, Yiwen Liu, Rebecca Fine, Kejal Amin, Eric Chang, Nicholas Defilippo, Craig Keating, Yuxin Liu, Michael Mankbadi, Dayna Mcmanus, Stephen Y Wang, Christina Price, Robert D Bona, Cassius Iyad Ochoa Chaar, Hyung J Chun, Alexander B Pine, Henry M Rinder, Jonathan M Siner, Donna S Neuberg, Kent A Owusu, Alfred Ian Lee
American Journal of Hematology, doi:10.1002/ajh.26102
Thrombotic complications occur at high rates in hospitalized patients with COVID-19, yet the impact of intensive antithrombotic therapy on mortality is uncertain. We examined in-hospital mortality with intermediate-compared to prophylactic-dose anticoagulation, and separately with in-hospital aspirin compared to no antiplatelet therapy, in a large, retrospective study of 2785 hospitalized adult COVID-19 patients. In this analysis, we established two separate, nested cohorts of patients (a) who received intermediate-or prophylactic-dose anticoagulation ("anticoagulation cohort", N = 1624), or (b) who were not on home antiplatelet therapy and received either in-hospital aspirin or no antiplatelet therapy ("aspirin cohort", N = 1956). To minimize bias and adjust for confounding factors, we incorporated propensity score matching and multivariable regression utilizing various markers of illness severity and other patient-specific covariates, yielding treatment groups with well-balanced
ETHICS APPROVAL STATEMENT This study was approved by the Yale Institutional Review Board (HIC 2000027792). PATIENT CONSENT STATEMENT Patient consent was not mandated for this study. Permission to reproduce material from other sources: No material from other sources is included in this study. CLINICAL TRIAL REGISTRATION This study was not a clinical trial. SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article.
References
Ackermann, Verleden, Kuehnel, Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19, N Engl J Med
Adam, Zacharowski, Miesbach, A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients, Thromb Res
Al-Samkari, Leaf, Dzik, COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection, Blood
Alarhayem, Muir, Jenkins, Application of electronic medical record-derived analytics in critical care: Rothman index predicts mortality and readmissions in surgical intensive care unit patients, J Trauma Acute Care Surg
Barnes, Burnett, Allen, Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, J Thromb Thrombolysis
Barrett, Moore, Yaffe, Moore, ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment, J Thromb Haemost
Blombery, Scully, Management of thrombotic thrombocytopenic purpura: current perspectives, J Blood Med
Carsana, Sonzogni, Nasr, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-Centre descriptive study, Lancet Infect Dis
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19, Anesth Analg, doi:10.1213/ANE.0000000000005292
Chowdhury, Moores, Connors, Anticoagulation in hospitalized patients with Covid-19, N Engl J Med
Connors, Levy, COVID-19 and its implications for thrombosis and anticoagulation, Blood
Ferguson, Volk, Vondracek, Flanigan, Chernaik, Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: a retrospective cohort study, J Clin Pharmacol
Ferrandis, Llau, Quintana, COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?, Crit Care
Fine, Gray, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Goshua, Pine, Meizlish, Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, crosssectional study, Lancet Haematol
Gray, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat
Gupta, Hayek, Wang, Factors associated with death in critically ill patients with coronavirus disease 2019 in the US, JAMA Intern Med
Hernan, Logan, Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease, Epidemiology
Hgs, Leaf, Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States, Res Pract Thromb Haemost, doi:10.7326/M20-6739
Ho, Dusendang, Schmittdiel, Kavecansky, Tavakoli et al., Anticoagulant and antiplatelet use not associated with improvement in severe outcomes in COVID-19 patients, Blood
Hottz, Azevedo-Quintanilha, Palhinha, Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19, Blood
Ionescu, Nair, Konde, Increasing doses of anticoagulation are associated with improved survival in hospitalized COVID-19 patients
Kashi, Jacquin, Dakhil, Severe arterial thrombosis associated with Covid-19 infection, Thromb Res
Lowenstein, Solomon, Severe COVID-19 is a microvascular disease, Circulation
Manne, Denorme, Middleton, Platelet gene expression and function in patients with COVID-19, Blood
Merkler, Parikh, Mir, Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza, JAMA Neurol
Moores, Tritschler, Brosnahan, Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report, Chest
Nadkarni, Bagiella, Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19, J Am Coll Cardiol
Nakazawa, Ishizu, Immunothrombosis in severe COVID-19, EBioMedicine
Nopp, Moik, Jilma, Pabinger, Ay, Risk of venous thromboembolism in patients with COVID-19: a systematic review and metaanalysis, Res Pract Thromb Haemost
Paranjpe, Fuster, Lala, Association of Treatment Dose Anticoagulation with in-Hospital Survival among Hospitalized Patients with COVID-19, J Am Coll Cardiol
Pesavento, Ceccato, Pasquetto, The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience, J Thromb Haemost
Petrilli, Jones, Yang, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new York City: prospective cohort study, BMJ
Reynolds, Adhikari, Pulgarin, Renin-angiotensinaldosterone system inhibitors and risk of Covid-19, N Engl J Med
Rothman, Rothman, Beals, Development and validation of a continuous measure of patient condition using the electronic medical record, J Biomed Inform
Spyropoulos, Levy, Ageno, Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost
Sturmer, Wyss, Glynn, Brookhart, Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs, J Intern Med
Taccone, Gevenois, Peluso, Higher intensity Thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients, Crit Care Med
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Trigonis, Holt, Yuan, Incidence of venous thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation, Crit Care Med
Wengerter, Pei, Asuzu, Davis, Rothman index variability predicts clinical deterioration and rapid response activation, Am J Surg
Zhang, Yan, Fan, D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19, J Thromb Haemost
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit